Cobb Lauren Patterson, Gaillard Stephanie, Wang Yihong, Shih Ie-Ming, Secord Angeles Alvarez
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710 USA.
Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710 USA.
Gynecol Oncol Res Pract. 2015 May 12;2:1. doi: 10.1186/s40661-015-0008-z. eCollection 2015.
Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer have proposed two primary histologic groups that encompass the standard histologic subtypes. Recent data suggest that these groupings no longer accurately reflect our knowledge surrounding these cancers. In this review, we propose that epithelial ovarian, tubal, and peritoneal carcinomas represent a spectrum of disease that originates in the Mullerian compartment. We will discuss the incidence, classification, origin, molecular determinants, and pathologic analysis of these cancers that support the conclusion they should be collectively referred to as adenocarcinomas of Mullerian origin. As our understanding of the molecular and pathologic profiling of adenocarcinomas of Mullerian origin advances, we anticipate treatment paradigms will shift towards genomic driven therapeutic interventions.
传统上,上皮性卵巢癌、输卵管癌和腹膜癌被视为具有不同起源、发病机制、临床特征和预后的独立实体。此外,先前的卵巢癌分类系统提出了两个主要的组织学组,涵盖了标准的组织学亚型。最近的数据表明,这些分组不再准确反映我们对这些癌症的认识。在本综述中,我们提出上皮性卵巢癌、输卵管癌和腹膜癌代表了起源于苗勒管腔室的一系列疾病。我们将讨论这些癌症的发病率、分类、起源、分子决定因素和病理分析,这些支持了它们应统称为苗勒管起源腺癌的结论。随着我们对苗勒管起源腺癌的分子和病理特征的理解不断深入,我们预计治疗模式将转向基因组驱动的治疗干预。